Cardiol Therapeutics Inc. (TSE:CRDL – Get Free Report) dropped 2.1% during trading on Friday . The stock traded as low as C$1.85 and last traded at C$1.89. Approximately 80,575 shares changed hands during mid-day trading, a decline of 40% from the average daily volume of 135,165 shares. The stock had previously closed at C$1.93.
Cardiol Therapeutics Stock Down 2.1 %
The company has a market cap of C$132.07 million, a PE ratio of -4.30 and a beta of 0.70. The business has a fifty day simple moving average of C$2.44 and a two-hundred day simple moving average of C$2.75. The company has a current ratio of 2.39, a quick ratio of 6.84 and a debt-to-equity ratio of 1.07.
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
- Five stocks we like better than Cardiol Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is Short Interest? How to Use It
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
